Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | ITK | Q08881 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 9/20 | 0.37 |
| ▸ | CLK2 | P49760 | 8/20 | 0.37 |
| ▸ | CLK3 | P49761 | 8/20 | 0.37 |
| ▸ | GSK3A | P49840 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.34 |
| ▸ | CHKA | P35790 | 1/20 | 0.34 |
| ▸ | CRHBP | P24387 | 1/20 | 0.34 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | CLK1 | P49759 | 1/20 | 0.34 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.34 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL593340 | 0.87 | VCP (0.41) | ITKGSK3BTP53CHKA | |
| SCHEMBL1617074 | 0.85 | KDR (0.44) | ITK | |
| SCHEMBL593398 | 0.85 | SMN1; SMN2 (0.52) | ITKKDM4E | |
| SCHEMBL593993 | 0.84 | KDR (0.34) | ITK | |
| SCHEMBL594521 | 0.84 | SYK (0.33) | ITK | |
| SCHEMBL594040 | 0.83 | KDR (0.34) | ITKKDM4ECRHBPCRHR2SLC2A1 | |
| SCHEMBL594261 | 0.82 | SLC6A3 (0.35) | ITKKDM4E | |
| SCHEMBL593587 | 0.81 | HTR2B (0.40) | TP53 | |
| SCHEMBL593955 | 0.80 | KDR (0.39) | ITKGSK3AGSK3BKDM4ESLC2A1 | |
| SCHEMBL593777 | 0.79 | IDO1 (0.40) | IDO1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2325186-B1 | Fused Bicyclic mTor Inhibitors | OSI PHARMACEUTICALS LLC (US) | 2014-10-08 | — | — | EP | disclosed |
| US-8796455-B2 | Fused bicyclic mTOR inhibitors | OSI Pharmaceuticals, LLC (US) | 2014-08-05 | — | — | US | disclosed |
| US-8586546-B2 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2385053-B1 | Intermediates for the preparation of fused bicyclic mTOR inhibitors | OSI PHARM INC (US) | 2013-10-02 | — | — | EP | disclosed |
| US-20130165651-A1 | FUSED BICYCLIC mTOR INHIBITORS | OSI Pharmaceuticals, LLC | 2013-06-27 | — | — | US | disclosed |
| US-20120207767-A1 | Combined Treatment with an EGFR Kinase Inhibitor and an Agent that Sensitizes Tumor Cells to the Effects of EGFR Kinase Inhibitors | OSI PHARMACEUTICALS, LLC. | 2012-08-16 | — | — | US | disclosed |
| US-8114846-B2 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2012-02-14 | — | — | US | disclosed |
| EP-2385053-A2 | Intermediates for the preparation of fused bicyclic mTOR inhibitors | OSI Pharmaceuticals, Inc. (US) | 2011-11-09 | — | — | EP | disclosed |
| US-7943767-B2 | Fused bicyclic mTOR inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2011-05-17 | — | — | US | disclosed |
| EP-1951724-B1 | FUSED BICYCLIC mTOR INHIBITORS | OSI PHARM INC (US) | 2011-04-27 | — | — | EP | disclosed |
| US-20100166776-A1 | COMBINED TREATMENT WITH AN EGFR KINASE INHIBITOR AND AN AGENT THAT SENSITIZES TUMOR CELLS TO THE EFFECTS OF EGFR KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. | 2010-07-01 | — | — | US | disclosed |
| US-20100099679-A1 | FUSED BICYCLIC mTOR INHIBITORS | OSI PHARMACEUTICALS, INC. | 2010-04-22 | — | — | US | disclosed |
| US-7700594-B2 | mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer | OSI PHARMACEUTICALS, INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-7651687-B2 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20090274698-A1 | Combination anti-cancer therapy | OSI PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20070280928-A1 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070112005-A1 | mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer | OSI PHARMACEUTICALS, INC. | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120207767-A1 | Combined Treatment with an EGFR Kinase Inhibitor and an Agent that Sensitizes Tumor Cells to the Effects of EGFR Kinase Inhibitors | EGFR, ERBB2, MTOR | IDO1 3956/4885ITK 232/4885DYRK1A 366/4885 |
| US-20100099679-A1 | FUSED BICYCLIC mTOR INHIBITORS | MTOR, RICTOR, MAPKAP1 | IDO1 4705/4885ITK 1741/4885DYRK1A 3350/4885 |
| US-20130165651-A1 | FUSED BICYCLIC mTOR INHIBITORS | MTOR, RICTOR, MAPKAP1 | IDO1 4705/4885ITK 1741/4885DYRK1A 3350/4885 |
| US-20090274698-A1 | Combination anti-cancer therapy | MTOR, RICTOR, AKT1 | IDO1 3505/4885ITK 921/4885DYRK1A 1857/4885 |
| US-20070280928-A1 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | EGFR, ERBB2, RICTOR | IDO1 4394/4885ITK 186/4885DYRK1A 306/4885 |
| US-20100166776-A1 | COMBINED TREATMENT WITH AN EGFR KINASE INHIBITOR AND AN AGENT THAT SENSITIZES TUMOR CELLS TO THE EFFECTS OF EGFR KINASE INHIBITORS | EGFR, ERBB2, RICTOR | IDO1 4394/4885ITK 186/4885DYRK1A 306/4885 |
| US-20070112005-A1 | mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer | MTOR, MAPKAP1, RPS6KA1 | IDO1 3757/4885ITK 532/4885DYRK1A 3233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.